ProSci research-grade biosimilars

Beyond therapeutics, monoclonal antibodies shown to be effective in the clinic can help to facilitate laboratory research. Researchers use mAbs, also known as biosimilars, as tools to research novel therapies and uncover effective off-target applications. With known and approved data on toxicity and efficacy, researchers use these biologics as benchmarks in their studies, allowing them to accelerate their findings from bench to clinic.

ProSci offers more than 800 research-grade biosimilar antibodies in the following research areas: cancer, pain, blood-related diseases, bacterial infection, neurodegenerative, asthma, psoriasis and other dermatitis, rheumatoid arthritis and osteoporosis, inflammatory diseases, Crohn’s disease, virus infection, and diabetes and other autoimmune diseases.